Last reviewed · How we verify
NCT02800382
Bronchoalveolar Lavage Liq To Distinguish Benign and Malignant Pulmonary Diseases
NA trial testing Take samples in Lung Diseases in 44 participants. Completed in 1 June 2016.
1 December 2013
Quick facts
| Lead sponsor | Izmir Dr Suat Seren Chest Diseases and Surgery Education and Research Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | factorial |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 44 |
| Start date | 1 January 2012 |
| Primary completion | 1 December 2013 |
| Estimated completion | 1 June 2016 |
Drugs / interventions tested
- Take samples
Conditions studied
- Lung Diseases — all drugs for Lung Diseases →
Sponsor
Izmir Dr Suat Seren Chest Diseases and Surgery Education and Research Hospital
Who can join
18 and older, any sex, with Lung Diseases. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Difference of Paraoxonase Serum and BAL Levels between malignant and benign lung diseases
Time frame: 3 month
Paraoxonase Measurement: Before bronchoscopy, 10 cc of blood were drawn from all patients via the cubital vein in sterile conditions. 16x100 mm Ayset tube was placed in two biochemistry tube. BAL material and a tube of blood sample were sent to The Microbiology Laboratory after the operation. The other one was sent to The Biochemistry Laboratory. Whole blood and BAL samples were centrifuged at 3
Sponsor's own description
Lipid per oxidation final products and free oxygen radicals are thought as initiator role for developing of cancer in the body. Level of paraoxonase in the patients with cancer varies. In this research, the investigators investigated the contribution of level of serum and bronchoalveolar lavage paraoxonase in the differentiation of benign and malignant lung disease patients. This research includes the patients that are diagnosis of lung cancer (research group) and benign pulmonary disease (control group) participated by accepted fiberoptic bronchoscopy (FOB).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02800382
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Diseases
Currently open trials in the same condition.
- NCT07356076 — The Use of Electrical Impedance Tomography (EIT) in Pulmonary Diseases · recruiting
- NCT07243964 — Multi-Omics-Based Prediction of Allograft Dysfunction After Lung Transplantation · recruiting
- NCT07270744 — Data Collection Using Eko Devices in a Clinical Setting · recruiting
- NCT07227376 — Data Collection Using Eko Digital Devices in a Clinical Setting · recruiting
- NCT06917573 — PALACE: Cemiplimab Trial According to ctDNA Levels · Phase 2 · recruiting
Other Izmir Dr Suat Seren Chest Diseases and Surgery Education and Research Hospital trials
Trials by the same sponsor.
- NCT05537974 — Open Suction vs. Closed Suction in ARDS · NA · completed
- NCT05435001 — Screening of Sleep Apnea by Holter Electrocardiography: Validation of Heart Rate Variability Analysis Algorithm · NA · completed
- NCT05053061 — Telerehabilitation in COPD · NA · recruiting
- NCT04873336 — Closed Loop Ventilation in Patients With COVID-19 · completed
- NCT04715919 — Long Term Outcomes of Coronavirus Disease-19 (COVID-19) · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02800382 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Izmir Dr Suat Seren Chest Diseases and Surgery Education and Research Hospital
- Last refreshed: 9 June 2016
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02800382.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing